VICTORY: Merck's Zontivity 1st PAR-1 antiplatelet OK'd in US
This article was originally published in Scrip
Executive Summary
After gaining the backing of an FDA panel of experts in January, it was highly likely Merck would win US regulators' blessing to market Zontivity (vorapaxar) – a drug once thought dead in the water – as an adjunctive therapy to reduce atherothrombotic events in patients with a history of myocardial infarction (MI), although there was some skepticism on the part of the agency's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on the firm's data.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.